



SYNTHESIS, IDENTIFICATION AND EVALUATION OF ANTIMICROBIAL ACTIVITY OF SOME NEW N-SUBSTITUTED-2-(METHYLTHIO) BENZIMIDAZOLE CONTAINING HETEROCYCLIC RING

Hala Ayad M. Rasheed^{1*}, Suaad M. H. Al-Majidi¹

Department of Chemistry, College of Science, University of Baghdad, Baghdad, Iraq

*Corresponding author's e-mail: halaayad2002@yahoo.com

ABSTRACT

New derivatives of 1,2,3-triazole and pyrazole were obtained from the work that was conducted in this research. Firstly; reaction of 2-mercaptobenzimidazole (2-MBI) in a basic condition with methyl iodide gave 2-(methylthio)-1H-benzo[d]imidazole [I] then compound [I] was reacted with sodium hydride in DMF at (0 °C) to bring forth the salt of compound [I]; subsequently, the produced salt was reacted with chloroacetylchloride to produce 2-chloro-1-(2-(methylthio)-1H-benzo[d]imidazol-1-yl)ethanone as starting compound [II]. Thereafter, reaction of compound [II] was carried out through two pathways: first pathway, involved a reaction with sodium azide to give 2-azido-1-(2-(methylthio)-1H-benzo[d]imidazol-1-yl)ethanone compound [III] which was entered in 1,3-dipolar cycloaddition with α,β -unsaturated carbonyl compounds [a-e] to give 1,2,3-triazole derivatives [IV_{a-e}]. While the second pathway was achieved by reaction with *p*-phenylenediamine to give compound [V] then diazotization to produce diazonium salt which was, in turn, coupled with acetylacetone to give compound [VI]. Subsequently, the product of the previous reaction was reacted with hydrazine derivatives [a-e] to give pyrazole derivatives [VII_{a-e}]. The new prepared compounds were identified by [FTIR, ¹H-NMR and ¹³C-NMR] and their physical properties were measured. Furthermore, we have evaluated the effect of some prepared compounds on some bacterial and fungal strains.

KEYWORDS: 2-MBI, 2-(methylthio) benzimidazole, 1,2,3-triazole, pyrazole, anti-microbial.

INTRODUCTION

Heterocyclic compounds constitute a key-component in numerous natural products, to name a few; vitamins, hormones, alkaloids, a wide range of antibiotics, pharmaceutical products, herbicides, anti-aging medicines and plenty other industrial products of high importance (different types of dyes, corrosion inhibitors, stabilizing agents, sensitizers, etc) ⁽¹⁾. In fact, more than half of all known organic compounds are heterocycles ⁽²⁾. So far, 2-Mercaptobenzimidazoles are the most frequently encountered heterocyclic in medicinal and industrial chemistry ⁽³⁾ with a wide variety of essential biological activities such as anti-histamine, anti-microbial, neutropic and analgesic activities ⁽⁴⁾. 2-Mercaptobenzimidazole compounds contain both -NH and -SH groups and alkylation was noticed to be more inclined to occur on sulphur rather than nitrogen due to higher nucleophilicity of sulphur in comparison with nitrogen ⁽⁵⁾. Moreover; alkylation of 2-Mercapto benzimidazole under basic conditions using different alkyl halides and aryl halides give the thio ether derivatives ⁽⁶⁾. On other hand, Triazoles are five-membered heterocyclic compounds which contain three nitrogen atoms ⁽⁷⁾. Different synthetic methodologies have been utilized recently to prepare Triazole ring system 1,3-Dipolar cycloaddition reactions of azides with (alkyne ⁽⁸⁾, α,β -unsaturated ketones with azides ⁽⁹⁾ and from arylglyoxaloxime ⁽¹⁰⁾. Many 1, 2, 3-triazoles are found to be potent anti-microbial ⁽¹¹⁾, anti-inflammatory ⁽¹²⁾, anti-malarial ⁽¹³⁾, anti-viral agents ⁽¹⁴⁾ and a unit of high

significance with anticancer profile in many of the human cell lines ⁽¹⁵⁾. Pyrazoles are heterocyclic organic compounds characterized by a five-membered ring of three carbon atoms and two adjacent nitrogen centers ⁽¹⁶⁾. Generally speaking, pyrazoles are synthesized by reaction of 1,3-diketones with hydrazine, 1,3-dipolar cycloaddition of diazo compounds with alkynes and reaction of α,β -unsaturated aldehydes and ketones with hydrazine ⁽¹⁷⁾. Interestingly enough; a large number of pyrazoles have been produced and some of them gained applications on the clinical level as well. These compounds have diverse biological activities such as; anti-microbial ⁽¹⁸⁾, anti-cancer ⁽¹⁹⁾, anti-inflammatory ⁽²⁰⁾, anti-microbial and anti-oxidant ⁽²¹⁾. In this research we aimed to synthesize new 2-chloro-1-(2-(methylthio)-1H-benzo[d]imidazol-1-yl)ethanone derivatives including 1,2,3-triazole and pyrazole moieties and evaluation of its' antimicrobial activities.

MATERIALS & METHODS

All chemicals used were supplied by: Merck, BDH, Fluka and sigma Aldrich chemicals companies. The melting point was recorded using Gallenkamp, electro-thermal melting point apparatus. Infrared spectra were recorded using (FTIR) 8400s Fourier transitions infrared spectrometer shimadzu, Japan, (KBr) disc in (4000-600) cm⁻¹ spectral range, in the Department of Chemistry, College of Science, University of Baghdad and Research Laboratory, College of Pharmacy, University of Al-Mustansiriyah. ¹H-NMR & ¹³CNMR spectra were

recorded on near magnetic resonance Bruker, Ultra-shield (400) MHz, in the University of Ain-Shams, College of Pharmacy, Egypt. Also; DMSO-d₆ was used as a solvent and Central Laboratory Isfahan University, Iran. CDCl₃ was used as solvent.

Synthesis of 2-(methylthio)-1H-benzo[d]imidazole []

This compound was prepared according to the literature's procedure.⁽⁶⁾

Synthesis of 2-chloro-1-(2-(methylthio)-1H-benzo-[d]imidazol-1-yl)ethanone []⁽²²⁾

Solution of compound [I] (1gm, 0.006 mole) in anhydrous dimethyl formamide (DMF) (7ml) was cooled to 0°C, and Sodium hydride (0.14gm, 0.006 mole) in small a portions was added. The solution was stirred for (30 minutes) then Chloroacetyl chloride (0.5ml, 0.006mole) was added drop wise. The mixture was stirred for 10 minutes at 0°C, and then stirred at room temperature for (4 hours). The solvent was evaporated then poured into ice water and filtered.


The precipitate was recrystallized with ethanol to give a brown powder.

Synthesis of 2-azido-1-(2-(methylthio)-1H-benzo[d]imidazol-1-yl)ethanone []⁽²³⁾

Consequently, Sodium azide (0.52gm, 0.008 mole) was added to the solution of compound [II] (1gm, 0.004 mole) in absolute ethanol (10ml). The mixture was refluxed for (6 hours) with stirring. The solvent was evaporated then light brown precipitate was washed with cold water, filtrated and recrystallized with ethanol.

General Procedure for Synthesis of 2-(methylthio)-1H-benzo[d]imidazole triazole moiety derivatives [Va-e]:⁽²³⁾

Afterwards, α,β -unsaturated carbonyl compounds (0.001 mole) was added to the solution of compound [III] (0.25gm, 0.001 mole) in absolute ethanol (10ml). The mixture was refluxed for (24 hours). The solvent was evaporated and the residue was washed with diethyl ether. As shown in Scheme 1.



SCHEME 1: Shows the synthesis of the target compounds (IV_{a-e})

Synthesis of 2-((4-aminophenyl)amino)-1-(2-(methylthio)-1H-benzo[d]imidazol-1-yl)ethanone [V]⁽²⁴⁾

Compound [III] (0.72gm, 0.003 mole) was dissolved in absolute ethanol (10ml) then anhydrous potassium carbonate (0.41gm, 0.003 mole) was added. The mixture was stirred then *p*-phenylenediamine (0.32gm, 0.003 mole) solution in absolute ethanol (10ml) was added drop-wise. The mixture was refluxed and stirred for (8 hours). The solvent was evaporated and the product was washed with cold water, filtrated and recrystallized with (ethanol-water).


Synthesis of 3-(2-(4-((2-(2-(methylthio)-1H-benzo[d]imidazol-1-yl)-2-oxoethyl) amino) phenyl) hydrazono) pentane-2,4-dione [VI]⁽²⁵⁾

Compound [V] (0.31gm, 0.001 mole) was dissolved in concentrated HCl (2ml) and cooled in an ice bath at 0-5

°C, then drop-by-drop solution of Sodium nitrite (0.07gm, 0.001 mole) in (5ml) water was added to it, stirred for (30minutes) and the temperature was maintained at 0-5 °C. The mixture was added drop-by-drop to Acetyl acetone (0.1gm, 0.001 mole), Sodium acetate (0.16gm, 0.002 mole) in absolute ethanol (5ml) solution. The mixture was stirred for (30 minutes). Then after the solvent was left to evaporate, the product was recrystallized with ethanol.

General Procedure for Synthesis of 2-(methylthio)-1H-benzo[d]imidazole pyrazole moiety derivatives (VIIa-e):⁽²⁶⁾

Hydrazine derivatives compounds (0.0006mol) were added to compound [VI] (0.25gm, 0.0006mol) in absolute ethanol (10ml) solution. The mixture was stirred and refluxed for (10-12 hours), the solvent was evaporated and the product was washed with water then diethyl ether. As shown in Scheme 2.



SCHEME 2. Shows the synthesis of the target compounds (VII a-e)

Anti-microbial activity test: ^(27,28)

Some of the prepared compounds were tested clinically against two strains of bacteria (+ve) bacterial isolates as: *Streptococcus faecalis* from the (ear) and *Staphylococcus aureus* from the (wound) and two strains from clinical gram (–ve) bacterial isolates as: *Escherichia coli* from (urine) and *Klebsiella pneumonia* from the (ear) in addition to *Candida albicans* from (vagina) as fungus

isolate. The anti-microbial activities of each derivative compounds were studied by using agar well diffusion method, which used Mueller Hinton Agar (MHA) and Blood Agar Base (BAB). DMSO used as the negative controller and Ciprofloxacin was used as a standard drug for antimicrobial. All tests were performed in college of Pharmacy / university of Al-mustansiriyah. The results are displayed in Table 1.

TABLE 1: antimicrobial activity of synthesized compounds

Sample code and standard	Concentration (µg/ml)	Zone of inhibition (mm)				
		Gram positive		Gram negative		Fungal
		Strepto.	Staphylo.	<i>E. coli</i>	<i>Klebsiella</i>	<i>Candida al.</i>
IV _a	800	-	12	2	-	2
	400	-	10	18*	-	4
IV _b	800	-	14	18*	-	6
	400	-	14	12*	-	4
IV _c	800	-	10	8	-	4
	400	-	10	4	-	2
IV _d	800	-	12	4	-	4
	400	-	12	4	-	2
IV _e	800	6	12	4	-	4
	400	4	12	4	-	6
VII _a	800	4	20*	6	-	8
	400	6	12	4	-	6
VII _b	800	4	12	6	-	4
	400	4	14	4	-	2
VII _c	800	4	12	4	-	-
	400	4	14	4	-	4
VII _d	800	2	12	12*	-	18*
	400	4	14	6	-	18*
VII _e	800	4	12	6	-	6
	400	4	10	4	-	6
Ciprofloxacin	10	40	16	-	30	12
DMSO	-	-	-	-	-	-

Zone of inhibition: (-) no inhibition; (3-6) weak; (7-10) moderate; (11-15) strong

RESULTS & DISCUSSION

Synthesis of the target compounds (IV_{a-e} & VII_{a-e}) were detected by spectral (FTIR, ¹H-NMR & ¹³C-NMR), sharp band in compound (II) in 1718 cm⁻¹ that belongs to amide group because we have -chloro to amide group that increased the frequency⁽²⁹⁾. While, in (¹H-NMR) the chemical shift disappeared at 12.5 ppm that belongs to (NH) and in (¹³C-NMR) the signal appeared at 173 ppm for (C=O) amide as show in tables (2-3).

On other hand, the absorbed band in 1437-1446 cm⁻¹ in compounds (IV_{a-e}) belongs to N=N group of triazole and disappeared at 2129 cm⁻¹ for azide group in compound [III]. In pyrazole compounds (VII_{a-e}) pathway synthesis, we have absorption band in compound (V) at 3369 (asym.) and (3323 sym.) for (NH₂) while in (¹H-NMR) we have

signal at 6.5 ppm for (NH₂) and 7.43 ppm for (NH) as show in tables (4-5). In compound (VI) was disappeared (NH₂) band in (FTIR) and signal in (¹H-NMR). The presence band in compound (VII_{a-e}) at 1435-1460 cm⁻¹ which indicate the formation N=N and disappeared 1730 cm⁻¹ that belonged to C=O of diketone in compound [VI] as show in tables (6-7). Table 1 shows the inhibition zones in (mm) of the mentioned derivatives. In comparison with standard drug (Ciprofloxacin), the antimicrobial activity showed that compounds (IV_{a-e} & VII_{a-e}) were specific for *Escherichia coli* bacteria while showed no activity for *Klebsiella pneumonia* while in *Streptococcus faecalis* bacterial showed weak activity. Some of the prepared compounds showed high activity for *Staphylococcus aureus* bacteria and *Candida albicans* fungi.

TABLE 2: physical properties and FTIR spectral data cm⁻¹ of compounds [2-MBI, ,]

Comp. NO.	Structure	Melting Point (C°)	Yield %	FTIR spectral data cm ⁻¹					
				(N-H)	(C-H) aroma.	(C-H) alipha.	(C=C) aroma.	(C=O) amide	Others
2-MBI		300-304	-	3155	3050	-	1465	-	(C=N Imidazole) 1622 (SH) 2764
		199-200	77	3220	3053	2960 2872	1465 1500	-	(C=N Imidazole) 1620 (C-S-C) 665
		122-124	85	-	3061	2955 2924 2854	1570 1502	1718	(C=N Imidazole) 1616 (C-Cl) 794

TABLE 3: ¹H-NMR and ¹³C-NMR spectral data (ppm) of compounds [,]

Com. No.	Structure	¹ H-NMR spectral data (ppm)	¹³ C-NMR spectral data (ppm)
		2.70 (s,3H,-CH ₃); 7.09-7.43 (m,4H,Ar-H); 12.68 (s,H,-NH)	-
		2.90 (s,3H,S-CH ₃); 4.74 (s,2H,-CH ₂ -Cl); 7.41-7.73 (m,4H, Ar-H)	40.81 (S-CH ₃); 70.79 (CH ₂); 113-139 (Ar); 156.33 (N=C-N); 173.60 (O=C-N)

TABLE 4: physical properties and FTIR spectral data cm^{-1} of compounds [, Va-e]







Com. NO.	Structure	Melting Point (C°)	Yield %	FTIR spectral data cm^{-1}					
				(C-H) aroma.	(C-H) alipha.	(C=N)	(C=C)	(C=O)	Others
		182-184	80	3053	2954 2924 2808	1616	1589- 1498	1710	(N ₃) 2129 1437
V _a		98-100	70	3053	2990 2958 2908	1625	1550- 1450	1856 1781 (anhyd.) 1710 (amide)	(N=N) 1446 (C-O-C) 1279
V _b		90-92	65	3063	2960 2918 2841	1620	1593 1525	1800 1726 (anhyd.) 1680 (amide)	(C-Cl) 1018 (N=N) 1446 (C-O-C) 1259
V _c		118-120	89	3055	2956 2924 2854	1612	1591- 1508	1731 (ketone) 1700 (amide)	(N=N) 1437
V _d		114-116	95	3057	2962 2926 2862	Overlap with amide	1589- 1496	1731 (ketone) 1684 (amide)	(N=N) 1438
V _e		122 (d.)	90	3053	2956 2924 2854	1633	1550- 1498	1720 (acid) 1687 (amide)	(N=N) 1440 (OH acid) 3300-2700

TABLE 5: ¹HNMR and ¹³CNMR spectral data (ppm) of compounds [V_b, V_d]






Com. NO.	Structure	¹ HNMR spectral data (ppm)	¹³ CNMR spectral data (ppm)
V _b		2.70 (s,3H,-S-CH ₃); 3.39 (s,2H,-CH ₂ -N); 7.08-7.49 (m,4H,Ar-H)	40.39 (CH ₃); 78.27 (CH ₂); 103.11 (C-Cl); 115.58-139.39 (Ar); 150.53 (N=C-N); 176.48 (O=C-N); 189.76 (O=C-O)
V _d		2.70 (s,3H,-S-CH ₃); 3.39 (s,2H,-CH ₂ -N); 5.77 (s,H,CH-quinone ring); 7.11-7.98 (m,8H, Ar-H)	40.39 (CH ₃); 78.34 (CH ₂); 85.56 (CH-N); 121.26 (Ar); 151.56 (N=C-N); 175.18 (O=C-N); 194.66 (C=O diketone)

TABLE 6: physical properties and FTIR spectral data cm^{-1} of compounds [V-V_a-e]

Com. NO.	Structure	Melting Point (C°)	Yield %	FTIR spectral data cm^{-1}					Others
				(NH)	(C-H) aroma.	(C-H) alipha.	(C=N)	(C=O)	
V		102-104	68	3215	3059	2926 2816	1618	1700	(p-NH ₂) 831 (NH ₂) 3369 (asy.) 3323 (sym.) (C=Caro.) 1600-1552 (C=C aro.) 1589-1512
V		78-80	93	3311	3058	2958 2924 2858	1624	1730 (ketone) 1700 (amide)	
V _a		81-83	80	3325	3049	2960 2949 2864	1624	1700	(N=N) 1435

V _b		70-72	69	3211	3039	2955 2856	1656	1705	(N=N) 1435
V _c		110 (d.)	75	3193	3099	2923 2854	1623	1701	(NO ₂) 1517 (asy.) 1344 (sym.) (N=N) 1458
V _d		160 (d.)	85	3342	3060	2962 2925 2864	1655	1696	(C-Br) 594 (N=N) 1438 (p-Br) 648
V _e		148 (d.)	86	3325	3097	2928 2852	1641- 1616	1700	(NO ₂) 1514 (asy.) 1330 (sym.) (N=N) 1460

TABLE 7: ¹HNMR and ¹³CNMR spectral data (ppm) of compounds [V, V_b, V_c, V_d]

Com. NO.	Structure	¹ HNMR spectral data (ppm)	¹³ CNMR spectral data (ppm)
V		2.51 (s, 3H, -CH ₃); 3.35 (d, 2H, -CH ₂); 6.50 (s, 2H, -NH ₂); 7.09-7.11 (m, 4H, Ar-H); 7.43 (t, H, -NH)	40.61 (CH ₃); 65 (CH ₂); 121.71 (Ar); 151.65 (N=C-N); 174.3 (O=C-N)
V		2.63 (s, 3H, -S-CH ₃); 2.76 (s, 6H, -CH ₃ -C=O); 3.05 (d, 2H, -CH ₂); 5.95 (s, H, -NH-N=C); 7.39-7.76 (m, 8H, Ar-H); 7.83 (t, H, -NH-CH ₂)	-
V _c		2.01 (s, 6H, -C=C-CH ₃); 2.98 (s, -S-CH ₃); 4.27 (t, 2H, -CH ₂ -NH); 7.44-7.82 (m, 12H, Ar-H); 8.40 (t, H, -CH ₂ -NH)	-
V _d		2.11 (s, 6H, -C=C-CH ₃); 2.83 (s, 3H, -S-CH ₃); 3.88 (t, 2H, -CH ₂ -NH); 7.33-7.53 (m, 12H, Ar-H); 8.30 (t, H, -CH ₂ -NH)	-

CONCLUSION

This work demonstrates the reactions involved in the synthesis of new heterocyclic compounds and hence, the detection of their antimicrobial activity. The antimicrobial activity of these compounds was evaluated against Gram-positive, Gram-negative bacteria and fungi. The target compounds (IVa-e & VIIa-e) showed more significant antimicrobial activity than a standard well-known drug. On the other hand, most of the compounds showed a moderately significant antimicrobial activity.

REFERENCES

- [1]. Mehdi, P., Hamed, C., Shirin, R. and Mohammadreza, D. (2016) new fluorescent heterocyclic systems from
- [2]. Theivendren, P. S., Caiado, R. J., Phadte, V. D. and Silveira, K. V. (2012) a mini review of pyrimidine and fused pyrimidine marketed drugs. *Res. In Pharmacy*. **2**, 01-09.
- [3]. Ali, K. K. (2007) phase-transfer catalyzed alkylation and acylation of 2-mercapto-5-methyl-1h-benzimidazole. *Phosphorus, Sulfur, and Silicon Phosphorus, Sulfur and Silicon and The Related Elements*. **182**, 815-823.
- [4]. Anandarajagopal, K., Ravi, N. T., Bothara, K. G., Anbu, J. S., Dineshkumar, C. and Promwichit, P.

imidazo[1,2-a]pyridine: design, synthesis, spectral studies and quantum-chemical investigations. *J. Molecular Structure*. **1129**, 105-112.

- (2010) 2-mercaptobenzimidazole derivatives: synthesis and anticonvulsant activity. *Adv. Appl. Sci. Res.* **1**, 132-138.
- [5]. Srinivas, S. R., Venkata, C. R. R. and Dubey, P. K. (2015) high efficient tandem synthesis of unsymmetrical substituted isomeric s,n-disubstituted-2-mercaptobenzimidazole. *Indian J. Chem.* **54b**, 892-832.
- [6]. Mohammed, R. A., Shetha F. N. and Amal, S. S. (2013) synthesis of 2-mercaptobenzimidazole and some of its derivatives. *J. Al-Nahrain Uni.* **16**, 77-83.
- [7]. Hayder, M. K. and Ezzat, H. Z. (2014) synthesis and characterization of some new benzotriazole derivatives via 1,3-dipolar cycloaddition reactions. *Int. J. Pharma. Sci.* **4**, 677-688.
- [8]. Piyush, C., Nupur, C. and Setu, G. (2011) click chemistry: a new approach for drug discovery. *Int. J. Of Pharma. Sci. Review and Res.* **10**, 111-117.
- [9]. Zhiyun, D., Kun Z. and Jian, W. (2015) organocatalytic 1,3-dipolar cycloaddition reaction of α,β -unsaturated ketone with azide through iminium catalysis. *Green Chem.* **17**, 781-784.
- [10]. Imran, A. K., Matloob, A., Sana, A., Muhammad, J. S., Ameer, F. Z., Syed, A. R. N. and Asim, M. (2015) recent advances in the synthesis of triazole derivatives. *Afinidad-Barcelona*. **569**, 64-67.
- [11]. Nimisha, S., Pandey, S. K. and Rama, P. T. (2010) Regioselective [3+2] cycloaddition of chalcones with a sugar azide: easy access to 1-(5-deoxy-D-xylofuranos-5-yl)-4,5-disubstituted-1H-1,2,3-triazoles. *Carbohydrate Res.* **345**, 1641-1648.
- [12]. Navabeh, N., Daryoush, Z., Maryam, G., Ameneh, A., Mehdi, F., Somayeh, M. and Milad, H. S. (2017) An efficient method for synthesis of some heterocyclic compounds containing 3-iminoisatin and 1,2,4-triazole using Fe₃O₄ magnetic nanoparticles. *J. of Sulfur Chem.*, 1-12.
- [13]. Wenqiang, T., Qing, L., Huali, W., Yan, L., Jingjing, Z., Fang, D. and Zhanyong, G. (2016) Synthesis, characterization, and antibacterial property of novel starch derivatives with 1,2,3-triazole. *Carbohydrate Polymers*. **142**, 1-7.
- [14]. Ying-Chun, W., Yu-Yang, X., Hong-En, Q., Heng-Shan, W., Ying-Ming, P. and Fu-Ping, H. (2014) Ce(OTf)₃ Catalyzed [3 + 2] Cycloaddition of Azides with Nitroolefins: Regioselective Synthesis of 1,5-Disubstituted 1,2,3-Triazoles. *The J. of Org. Chem.* **79**, 4463-9.
- [15]. Pardeep, S., Raghu, R. and Vipin, K. (2012) 1,2,3-triazole tethered b-lactam-chalcone bifunctional hybrids: synthesis and anticancer evaluation. *Europ J. Of Med. Chem.* **47**, 594-600.
- [16]. Taha, M. A. Eldebss (2014) recent advances on the synthesis of pyrazole-containing compounds of potent biological activities and study their chemical applications. *Asian J. Of Biochem. and Pharma. Res.* **4**, 356-384.
- [17]. Ajay, K. K. and Jayaroopa, p. (2013) pyrazoles: synthetic strategies and their pharmaceutical applications-an overview. *Int. J. Pharmtech Res.* **5**, 1473-1486.
- [18]. Güniz, k. . and Sevil . (2015) recent advances in bioactive pyrazoles. *Europ J. Of Med. Chem.* **97**, 786-815.
- [19]. Jin-Xia, M., Yan-Xia, S., Ming-Yan, Y., Zhao-Hui, S., Xing-Hai, L., Bao-Ju L. and Na-Bo, S. (2016) Design, Synthesis, DFT Study and Antifungal Activity of Pyrazolecarboxamide Derivatives. *Molecules*. **21**, 1-11.
- [20]. Aixue, S., Jia-Hai, Y., Haitao, Y., Wenchao, Z., Xiaolong, W. (2013) A new efficient synthesis of pyrazoles from hydrazonoyl halides and α -oxophosphonates. *Tetrahedron Lett.*
- [21]. Mohamed, A. E., Hala, F. R., Mohamed, R. S. and Mai, M. E. (2016) An Eco-Friendly Synthesis of Heterocyclic Moieties Condensed with Pyrazole System under Green Conditions and Their Biological Activity. *Green and Sustainable Chem.* **6**, 88-100.
- [22]. Suaad, M. H. Al-Majidi (2013) Synthesis, Characterization and Evaluation of Antimicrobial Activity of Several New N-Substituted Carbazole. *J. of Al-Nahrain Univ.* **16**, 67-79.
- [23]. Khitam, T. A. Al-Sultani, Suaad, M. H. Al-Majidi and Oday, H. R. Al-Jeilawi (2016) Synthesis, Identification and Evaluation Biological Activity for Some New Triazole, Triazoline and Tetrazoline Derivatives From 2-Mercapto-3-phenyl-4(3H)Quinazolinone *Iraqi J. Sci.* **57**, 295-308.
- [24]. Redhab, A. J. Alfraiji and Suaad, M. H. Al-Majidi (2014) Synthesis, Characterization and Evaluation of Antimicrobial Activity for New Heterocyclic Derivatives Containing Pentagonal, Hexagonal Rings. *Iraqi J. Sci.* **55**, 1694-1707.
- [25]. Patil, C. J., Manisha, P. C., Nilesh, R. P. and Vilas, S. W. (2015) Coupling reactions involving aryldiazonium salt: Part-II. Chemoselective condensation with acetyl acetone and antibacterial activity. *Der Chemica Sinica*. **6**, 115-121.
- [26]. Subramanyam, S., Raja, S., Jayaveera, K. N. and Sunil, K. K. (2012) Synthesis, Characterization and Biological Activity of 1, 8-Naphthyridine Nucleus Linked with Pyrazolinone, Pyrazole, Isoxazolinone and Isoxazole Derivatives. *Int. J. of Innovative Pharma. Res.* **3**, 187-193.
- [27]. Kuete, V., Eyong, G. and Folefoc, V. (2007) Antimicrobial activity of the methanolic extract and of the chemical constituents isolated from *Newbouldia laevis*. *Pharmazie*. **62**, 552-556.
- [28]. Neli, L., Yogendra, K. and Berington, M. (2011) In vitro antibacterial activity of alkaloid extract from stem bark of *Mahonia manipurensis* Takeda. *J. of Medicinal Plants Res.* **5**, 859-861.
- [29]. R. M. Silverstein, F. X. Webster, D. J. Kiemle, (2005) Spectrometric identification of organic compounds, John Wiley & Sons, USA, 7, 100.